---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-016792"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2026-02-18T23:59:59+00:00"
generated_at: "2026-05-16T02:17:13.113868+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics licenses SYN-020 to Rasayana for $300K upfront, up to $38M milestones

## Summary
- Upfront payment of $300,000 received; eligible for $16M development/regulatory and $22M sales milestones.
- Tiered single-digit royalties on net sales of SYN-020; Rasayana assumes all development and commercialization costs.
- SYN-020 is an oral IAP enzyme with Phase 1 safety data; Rasayana plans Phase 2 testing.
- Theriva to focus on lead pancreatic cancer program VCN-01 following out-license.

## SEC filing metadata
- accession: 0001104659-26-016792
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2026-02-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465926016792/0001104659-26-016792-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465926016792/tm266493d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-016792
- JSON: https://secwatch.observer/filing/0001104659-26-016792.json
- Plain text: https://secwatch.observer/filing/0001104659-26-016792.txt

## Key facts
- Material Agreements
  Theriva Biologics, Inc. entered into Agreement with Rasayana Therapeutics, Inc. valued at $300,000 (effective 2026-02-18).
  - Action: entry
  - Agreement: license
  - Counterparty: Rasayana Therapeutics, Inc.
  - Value: $300,000
  - Effective: 2026-02-18
  source text: On February 18, 2026 (the “Effective Date”), Theriva Biologics, Inc. (the “Company”) entered into a license agreement (the “Agreement”) with Rasayana Therapeutics, Inc. (“Rasayana”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/894158/000110465926016792/0001104659-26-016792-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.